<DOC>
	<DOCNO>NCT00592163</DOCNO>
	<brief_summary>A Phase I Study Oral ZIO-101-C Advanced Solid Tumors Lymphomas</brief_summary>
	<brief_title>Phase I Study Oral ZIO-101-C Advanced Solid Tumors Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<criteria>1 . Subjects histological cytological confirmation advance cancer refractory standard therapy condition . 2 . Men woman ≥18 year age . 3 . ECOG performance score ≤2 . 4 . Eligible subject MUST least one measurable lesion define RECIST guideline . If measurable disease restrict solitary lesion , neoplastic nature confirm cytology/histology . Measurable lesion MUST NOT previously irradiate field injected biological agent . Eligible subject lymphomas must measurable disease define revise International Working Group response criterion . 5 . Life expectancy ≥12 week . 6 . Adequate bone marrow , liver renal function assess follow laboratory requirement , conduct &lt; 2 week prior Baseline : Creatinine ≤1.5 × upper limit normal ( ULN ) OR calculate creatinine clearance ≥50 cc/min Total bilirubin ≤2 × ULN Alanine transaminase ( ALT ) aspartate transaminase ( AST ) ≤3 × ULN Granulocytes peripheral blood ≥1 × 109/L , hemoglobin ≥10 g/dL , platelet ≥50,000 /μL 7 . Adequate vascular access repeat blood sampling . 8 . Men woman childbearing potential must agree use effective contraception Screening duration Study participation . 9 . Written inform consent compliance ZIOPHARM policy Human Investigation Review Committee ( IEC/IRB ) jurisdiction site . 1 . New York Heart Association ( NYHA ) functional class ≥3 myocardial infarction within 6 month 2 . Uncontrolled cardiac arrhythmia asymptomatic atrial fibrillation ; QTc ≥450 msec ; ≥Grade 2 atrioventricular ( AV ) block leave bundle branch block ( LBBB ) ; document history prolong QTc . 3 . Pregnant and/or lactate woman . 4 . Uncontrolled systemic infection ( documented microbiological study ) . 5 . Metastatic brain meningeal tumor . 6 . Subjects seizure disorder require medication ( antiepileptic ) . 7 . History confusion dementia neurological condition could mask potential adverse response Study Drug , may include transient ischemic attack , Parkinson 's disease , thrombotic hemorrhagic stroke , Alzheimers , neurological disorder . 8 . Anticancer chemotherapy immunotherapy study within 4 week Study entry ( mitomycin C nitrosureas give within 6 week Study entry ) . 9 . Radiotherapy study within 3 week Study entry . 10 . Surgery within 4 week start Study Drug dose . 11 . Investigational drug therapy outside trial within 4 week Study entry . 12 . History invasive second primary malignancy diagnose within previous 3 year except Stage I endometrial/cervical carcinoma prostate carcinoma treat surgically , nonmelanoma skin cancer . 13 . Substance abuse , medical , psychological , social condition may interfere subject 's participation study evaluation Study result . 14 . Any condition unstable could jeopardize safety subject his/her compliance Study . 15 . Arsenic allergy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Arsenic</keyword>
</DOC>